Taysha Gene Therapies prices $200M public stock offering

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, according to a company press release.

The clinical-stage biotechnology company is also offering pre-funded warrants to purchase 833,333 shares of common stock at $5.999 per warrant to certain investors in lieu of common stock. All securities are being offered by Taysha.

Gross proceeds from the offering are expected to be approximately $200.0 million, before underwriting discounts, commissions, and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Taysha has granted underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book-running managers for the offering. Baird is acting as lead manager.

You May Also Be Interested In

• Zhongchao announces $5M registered direct offering at $1.10 per share
• Empery Digital invests $20M in data center developer Cardinal Data Power
• Disco names former Meta security executive to its board